Metastatic NSCLC - Non-Small Cell Lung Cancer
Oncology·MeSH: Carcinoma, Non-Small-Cell Lung
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
4 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Amivantamab | Merus N.V. (MRUS) |
Compare drugs
Frequently asked questions
How many drugs are in development for Metastatic NSCLC - Non-Small Cell Lung Cancer?
BioSniper tracks 4 drugs in development for Metastatic NSCLC - Non-Small Cell Lung Cancer across 2 companies.
How many clinical trials target Metastatic NSCLC - Non-Small Cell Lung Cancer?
There are 2 clinical trials targeting Metastatic NSCLC - Non-Small Cell Lung Cancer tracked by BioSniper.
What is the prevalence of Metastatic NSCLC - Non-Small Cell Lung Cancer?
The estimated prevalence of Metastatic NSCLC - Non-Small Cell Lung Cancer is approximately 75.0 per 100,000 population.
Deep-dive into Metastatic NSCLC - Non-Small Cell Lung Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis